New York-based Regeneron Pharmaceuticals Shares Performs Better

Regeneron Pharmaceuticals Inc. shares rallied 3.05% to $521.85 Wednesday. This proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.18% to 4,219.55 and Dow Jones Industrial Average DJIA falling 0.44% to 34,447.14.

Regeneron Pharmaceuticals Inc. closed $142.79 short of its 52-week high ($664.64), which the company reached on July 20th. The stock outperformed some of its competitors Wednesday, as Johnson & Johnson JNJ rose 1.35% to $165.59, Novartis AG ADR NVS rose 2.83% to $92.23, and Amgen Inc. AMGN rose 1.14% to $239.52.

Regeneron Pharmaceuticals Inc trading volume (767,501) remained 16,441 below its 50-day average volume of 783,942. Regeneron Pharmaceuticals is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth, which averaged 13.4% over the past three years and is estimated to grow 15.10% annually over the next three to five years.

New York-based Pharmaceuticals has a cash-to-debt ratio of 1.30, which is worse than 81% of the companies in the Biotechnology industry. The overall financial strength of Pharmaceuticals is 7 out of 10, which indicates that the financial strength of Regeneron Pharmaceuticals is fair. Over the past twelve months, the company had revenue of $9.2 billion and earnings of $35.33 a share. Its operating margin is 43.37%, which ranks better than 95% of the companies in the Biotechnology industry. Regeneron Pharmaceuticals is 13.4%, which ranks better than 66% of the companies in the Biotechnology industry. The 3-year average EBITDA growth is 22.5%, which ranks better than 67% of the companies in the Biotechnology industry.